Shiyu Zhou, PhD

Minghui Pharmaceutical
Shanghai, Shanghai, China (People's Republic)

Disclosure information not submitted.

Presentation(s):

• ORF49-08 - Subcutaneous MHB018A, a N Ovel Anti- IGF-1R VHH Antibody, for Thyroid Eye Disease (TED): Results from a Phase 1/2 Study in Patients with Active and Chronic TED

  Monday, June 15, 2026
  3:00 PM - 3:15 PM CT